BRAF and hepatocellular carcinoma: Even though AK2 showed tumor-suppressive roles and low AK2 expression correlated with poor prognosis of HCC patients, further studies focusing on the role of AK2 expression and AMP in HCC are required to offer possible therapeutic modalities in not only BRAF-driven cancers but cancers developing resistance to BRAF inhibitors.